RT Journal Article
SR Electronic
T1 Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily Practice
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.170587
DO 10.3899/jrheum.170587
A1 Céline Pereira-Gillion
A1 Mathilde Marot
A1 Isabelle Griffoul-Espitalier
A1 Lucia Andras
A1 Philippe Goupille
A1 Carine Salliot
YR 2018
UL http://www.jrheum.org/content/early/2018/01/24/jrheum.170587.abstract
AB Objective To assess the implementation of European recommendations for use of TNF inhibitors for spondyloarthritis (SpA), rheumatologists’ level of knowledge of and adherence to the recommendations, and potential barriers to the application of recommendations. Methods We conducted a retrospective study among 42 rheumatologists who initiated a first subcutaneous TNF inhibitor for SpA in 2013 or 2014. Thirty items from national and international recommendations were separated into 3 domains: indication, pretherapeutic monitoring, and management under TNF inhibitors. A standardized data collection procedure was used to gather data from medical files to assess the application of each recommendation. Questionnaires assessing the knowledge, level of adherence to each recommendation, and potential barriers to their implementation were sent to rheumatologists. Results Rheumatologists applied a mean of 60% of items from domains A and B, but less than 50% from domain C items. Recommendations regarding the search for previous infection and the prevention of future infections were the ones most often applied. However, < 60% of rheumatologists assessed cancer and other diseases before TNF inhibitor initiation. More than 95% of rheumatologists knew of the recommendations and had a high level of adherence. Lack of time, difficulties accessing specialized consultations, and lack of flexibility in the recommendations explained rheumatologists’ difficulties in applying the recommendations. Conclusion Despite high levels of knowledge of, and adherence to, recommendations for using TNF inhibitors for SpA, rheumatologists’ application was limited because of a lack of human and material resources.